NCT03009045View on ClinicalTrials.gov

Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 6, 2017

Primary Completion Date

March 23, 2021

Study Completion Date

August 6, 2021

Conditions
Bone and Joint Infection
Interventions
DRUG

Tedizolid

200mg oral tedizolid one pill per day

Trial Locations (2)

90502

Harbor-UCLA Medical Center, Torrance

Los Angeles BioMedical Research Institute (LA BioMed), Torrance

All Listed Sponsors
lead

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER

NCT03009045 - Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER) | Biotech Hunter | Biotech Hunter